shmt2

(Rac)-SHIN2, a serine hydroxymethyltransferase (SHMT) inhibitor, enhances NOTCH1-driven in vivo survival of primary T-ALL in mice and is useful for studying T-cell acute lymphoblastic leukemia (T-ALL).

SHIN1 (RZ-2994) is an inhibitor of human serine hydroxymethyltransferse 1(SHMT1) with IC50 of 5 nM and human serine hydroxymethyltransferse 2 (SHMT2) with an IC50 of 13 nM.

SHMT-IN-2 (compound 2) is a specific human SHMT1/2 small molecule inhibitor that acts on SHMT1 (IC50: 13 nM) and SHMT2 (IC50: 66 nM). SHMT-IN-2 inhibits the growth of many human cancer cells and is sensitive to B-cell lymphoma.

SHMT-IN-3 (Hit 1) is an inhibitor of SHMT1 and SHMT2, exhibiting an IC50 value of 0.53 µM for human SHMT1. It acts as a non-competitive inhibitor with respect to serine.

TD034 is a selective, reversible, non-covalent inhibitor of HDAC11, with an IC50 of 5.1 nM and a Ki of 1.5 nM. It does not inhibit other HDACs or sirtuins. TD034 inhibits the desuccinylation of SHMT2 (a substrate of HDAC11) and lowers YAP1 levels by inhibiting HDAC11. TD034 is applicable for lung cancer research.